deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT04150393

Safety and Tolerability Evaluation of MaaT033 (CIMON)

Safety Phase I Evaluation of MaaT033, a Lyophilized Full-ecosystem Gut Microbiota Delayed-release Capsule, In HeMatOlogy Malignant Patients Under iNtensive Chemotherapy (CIMON)

Sponsor: MaaT Pharma

Conditions Chemotherapy Effect Hematologic Diseases
Interventions MaaT033 capsule
Updated 7 times since 2019 Last updated: Apr 11, 2022 Started: Oct 20, 2020 Primary completion: Dec 13, 2021 Completion: Dec 13, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Chemotherapy Effect and Hematologic Diseases, this trial is completed. The trial is conducted by MaaT Pharma and has accumulated 7 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Dec 2019 – ~Oct 2020 · 10 months · monthly snapshotNot Yet Recruiting~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshotNot Yet Recruiting~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshotRecruiting~Jan 2021 – ~May 2022 · 16 months · monthly snapshotRecruiting~May 2022 – ~Jul 2024 · 26 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. May 2022 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Recruiting → Completed

  4. Jan 2021 — May 2022 [monthly]

    Recruiting PHASE1

  5. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

  1. Oct 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE1

  2. Dec 2019 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • MaaT Pharma
Data source: MaaT Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations